Ticker Details
REGENXBIO Inc. Regenxbio Inc is a biotechnology company. It is engaged in the development, commercialization and licensing of recombinant adeno-associated virus gene therapy.
IPO Date:	September 17, 2015
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$328.28M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.76 | 2.92%
Avg Daily Range (30 D):	$0.31 | 3.85%
Avg Daily Range (90 D):	$0.35 | 3.67%

Institutional Daily Volume
Avg Daily Volume:	.4M
Avg Daily Volume (30 D):	1.29M
Avg Daily Volume (90 D):	.96M

Trade Size
Avg Trade Size (Sh.):	74
Avg Trade Size (Sh.) (30 D):	87
Avg Trade Size (Sh.) (90 D):	77

Institutional Trades
Total Institutional Trades:	3,437
Avg Institutional Trade:	$1.91M
Avg Institutional Trade (30 D):	$.95M
Avg Institutional Trade (90 D):	$1.09M
Avg Institutional Trade Volume:	.07M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.13M
Avg Closing Trade (30 D):	$.94M
Avg Closing Trade (90 D):	$1.02M
Avg Closing Volume:	83.41K

News

Apr 15, 2026 @ 12:05 AM REGENXBIO Inc. Sued for Securities Law Violations ... Source: Djs Law Group

Apr 14, 2026 @ 7:51 PM INVESTOR ALERT: Pomerantz Law Firm Reminds Investo... Source: Pomerantz Llp

Apr 14, 2026 @ 7:46 PM INVESTOR ALERT: Pomerantz Law Firm Reminds Investo... Source: Pomerantz Llp

Apr 14, 2026 @ 1:00 PM Portnoy Law Firm Announces Class Action on Behalf ... Source: Portnoy Law Firm

Apr 12, 2026 @ 3:14 PM REGENXBIO DEADLINE: ROSEN, A LEADING AND RANKED FI... Source: Rosen Law Firm

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-5.6	$-1.72	$-1.3
Diluted EPS	$-5.6	$-1.72	$-1.3
Revenue	$87.82M	$6.39M	$30.34M
Gross Profit
Net Income / Loss	$-290.01M	$-90.05M	$-67.15M
Operating Income / Loss	$-256.69M	$-83.36M	$-57.64M
Cost of Revenue
Net Cash Flow	$-114.88M	$-19.24M	$-24.34M
PE Ratio